PubMed Health⌕ Search

Biomedical subjects

S Dündar

Publications and source records attributed to S Dündar.

At least 55 records · Page 3Linked to original sources
PubMed1996

Serum immunoglobulin E and soluble CD23 in patients with Graves' disease.

It is not clear whether the IgE system plays a role in the pathogenesis of Graves' disease which is an autoimmune disorder. The low-affinity receptor of IgE, which is known as CD23, is not simply a receptor, it has various functions related to immune cells. There is no information about its levels in Graves' disease. For these reasons, serum IgE and soluble CD23 levels were determined in 40 patients with thyroid disease, free from allergic disorders and/or parasitic infestations. Patients were divided into three groups: Group 1: Patients with Graves' disease (n = 15, age: 33.4 +/- 9.3, 9 women/6 men). Group 2: Patients with non-toxic diffuse or multinodular goitre (n = 15, age: 31.0 +/- 12.7, 13 women/2 men). Group 3: Patients with toxic nodular goitre (n = 10, age: 44.6 +/- 14.2, 9 women/1 men). There was no age or sex difference between the groups (p > 0.05). Serum IgE level was somewhat higher in group 1 as compared with the other two groups, but the difference was not statistically significant, the values showed great individual variations (Group 1: 99.60 +/- 105.10, Group 2: 47.89 +/- 53.42, Group 3: 46.48 +/- 35.90 IU/ml, p > 0.05). Serum sCD23 was detectable in 7 of 15 patients in group 1 (46.7%), 1 of 15 patients in group 2 (6.7%) and 1 of 10 patients in group 3 (10.0%). Serum sCD23 detectability ratio was found higher in patients with Graves' disease than in the other two groups (p < 0.02). Serum IgE levels were compared in sCD23 detectable and undetectable Graves' patients. The values were similar (sCD23 detectable group: 105.30 +/- 135.90, sCD23 undetectable group: 94.70 +/- 55.30 IU/ml, p > 0.05). These results suggest that increased detectability of sCD23 is associated with Graves' thyrotoxicosis. An underlying state of autoimmune thyroid disease may be a permissive factor for this phenomenon.

Adult↗
PubMed1996

The effect of desmopressin on platelet aggregation defect in systemic amyloidosis: a preliminary report.

Systemic amyloidosis may often be complicated with haemorrhagic tendency. The causes of this manifestation are factor deficiencies, hyperfibrinolysis and vasculopathy. In order to investigate the role of platelets, if any, we performed platelet aggregation tests with different aggregants in 10 patients with systemic amyloidosis due to familial Mediterranean fever and 10 healthy controls. Platelet aggregation was defective with different aggregants (ADP, epinephrine, collagen) in patients compared with controls. Platelet aggregation tests repeated after desmopressin (DDAVP) administration were normalized. These findings may suggest a role of a platelet aggregation defect in haemorrhagic diathesis complicating systemic amyloidosis. DDAVP may benefit patients with this disease in case of bleeding and before surgical interventions.

Adenosine Diphosphate↗
PubMed1996

Cytokines in Behçet's disease.

OBJECTIVE: Cytokines take place in immunologic and inflammatory reactions. The aim of this study was to describe the roles of various cytokines in the pathogenesis of Behçet's disease (BD). METHODS: Serum levels of interleukin-1 beta (IL-1 beta), interleukin-2 (IL-2), soluble IL-2 receptor (sIL-2R), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) were studied in 24 patients with active BD and 15 healthy adults as controls, by ELISA technique. Patients were separated into 2 groups according to the number of active organ systems (Group I: < 3 vs Group II: > or = 3). RESULTS: sIL-2R and age adjusted TNF-alpha levels were higher in patients with BD compared to controls (p = 0.004 and p = 0.002, respectively). But the median concentrations of Group I and Group II were not different. Serum levels of IL-1 beta, IL-2 and IL-6 were similar to the control group. CONCLUSION: High serum levels of sIL-2R and TNF-alpha indicate activation of the immune system in BD. But this finding may not be useful as a marker of disease activity.

Adolescent↗
PubMed1995

Increased erythropoietin response to venesection in erythrocytosic renal transplant patients.

Anaemia of end-stage chronic renal failure improves following successful kidney transplantation. However, erythrocytosis occurs in 6.8-17.3% of transplanted patients. Mechanism of post-transplant erythrocytosis (PTE) and its erythropoietin (Epo) dependence are still controversial. Firstly, we compared basal serum Epo levels of 10 PTE patients, 14 non-erythrocytosic renal transplant (non-PTE) patients and 12 healthy blood donors. Then we performed venesection in PTE patients and healthy blood donors and compared their Epo response to venesection 5 hours later. The mean basal serum Epo of 24.3 mU/ml was significantly higher in the PTE group than the 10.8 mU/ml in the non-PTE and 8.6 mU/ml in the healthy blood donor group (p < 0.01). Epo levels in the non-PTE group did not differ significantly from those of healthy blood donors (p > 0.05). Following venesection the mean serum Epo levels increased significantly in both groups, from 24.3 mU/ml to 67.7 mU/ml (p < 0.001) in the PTE group and from 8.6 to 12.1 mU/ml (p < 0.01) in the healthy blood donor group, but the increment in the PTE group was more marked. We conclude that PTE patients have elevated basal serum Epo levels and there is a feedback regulation of Epo secretion in these patients like in healthy blood donors, but in an exaggerated way.

Adult↗
PubMed1995

Sequential changes in serum thyroid peroxidase following radioiodine therapy of patients with differentiated thyroid carcinoma.

To determine the detectability and the time course of serum thyroid peroxidase (TPO) levels before and 1, 2, 4, and 6 months after 131I administration, we evaluated TPO in 13 selected patients with differentiated thyroid carcinoma (DTC) whose sera did not contain antimicrosomal or antithyroglobulin (Tg) antibodies. All patients received 131I therapy 6 or 8 weeks after thyroid surgery for ablation of the postsurgical thyroid remnant. Serum samples were also collected from 10 normal subjects. Measurement of TPO was carried out by using a new commercially available immunoluminometric assay with a sensitivity of 30 pg/mL. Serum Tg was measured by RIA with a sensitivity of 2.6 micrograms/L before and 6 months after 131I administration. In all patients, a standard total body scan was obtained before and 6 months after 131I administration. TPO was undetectable in all sera from normal subjects. However, serum TPO became detectable in all patients with DTC during the study, whereas rescans were either negative or positive and appeared not to be related to the radioiodine dose given, histology of the thyroid tumor, residual thyroid volume, TSH levels, or age of patients. However, a significant negative correlation was present between TPO levels before 131I administration and the time from surgery (r = -0.82, P < 0.001). Six of 13 patients had increased TPO levels 1 month after 131I administration. Serum TPO levels tended to decrease during follow-up in most patients (7 of 10) with a negative rescan. In 3 patients with positive rescans, TPO levels tended to increase during follow-up. Patients with negative rescans had values of serum TPO overlapping the range of values seen in patients with positive rescans, thus demonstrating the inability of TPO assay as a useful marker for following patients with DTC. We found no correlation between Tg and TPO levels measured before and 6 months after 131I administration, thereby excluding TPO levels as a marker for thyroid cancer. Our results suggest that TPO, unlike Tg, does not appear to be a useful marker for following patients with DTC.

Adult↗